Current assets increased 26.5%
Current assets changed +26.5% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Current assets changed +26.5% from the comparable as-filed period.
Inventory / revenue changed -1047 basis points from the comparable as-filed period.
Operating income changed -110.7% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Revenue changed +11.8% from the comparable as-filed period.
Working capital changed +18.5% from the comparable as-filed period.
Total assets changed +16.3% from the comparable as-filed period.
Operating cash-flow margin changed +365 basis points from the comparable as-filed period.
Receivables / revenue changed +286 basis points from the comparable as-filed period.
Trade receivables changed +17.6% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Current ratio changed -26.6% from the comparable as-filed period.
Capex / revenue changed +135 basis points from the comparable as-filed period.
Gross profit changed +17.4% from the comparable as-filed period.
Shares outstanding changed +0.2% from the comparable as-filed period. The change ranks at the 14th percentile of 7 prior comparable changes. This reverses 5 consecutive comparable moves in the opposite direction.
Stock-based compensation changed -24.9% from the comparable as-filed period.
Free-cash-flow margin changed +230 basis points from the comparable as-filed period.
Capital expenditure changed +1029.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Working capital / assets changed +128 basis points from the comparable as-filed period.
Inventory changed -3.1% from the comparable as-filed period.
Research & development changed +7.3% from the comparable as-filed period.
SBC / revenue changed -29 basis points from the comparable as-filed period.
Cost of revenue changed +4.5% from the comparable as-filed period.
Selling, general & administrative changed +4.3% from the comparable as-filed period.
R&D / revenue changed -29 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.